Stay updated on AEB1102 Dose Escalation in Advanced Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the AEB1102 Dose Escalation in Advanced Solid Tumors Clinical Trial page.

Latest updates to the AEB1102 Dose Escalation in Advanced Solid Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe study page now displays a 403 error page, replacing the previous content with an error layout. This blocks access to the trial details and location information shown on the page.SummaryDifference19%

- Check15 days agoChange DetectedThe page's revision indicator was updated from v3.6.6 to v3.7.0, signaling a software update to the page. No study details or content are changed as a result.SummaryDifference0.1%

- Check29 days agoChange DetectedThe page now displays Revision: v3.6.6, replacing the previous v3.6.5. This indicates a minor update to the page version.SummaryDifference0.1%

- Check50 days agoChange DetectedThe sponsor is updated to Immedica Pharma AB, and the study overview has been refreshed to reflect a first-in-human, phase 1 dose-escalation trial of AEB1102 (Co-ArgI-PEG). New expansion cohorts were added for Cutaneous Melanoma, Uveal Melanoma, and Small Cell Lung Cancer, dosed at 0.33 mg/kg, with corresponding enrollment details and updated timelines.SummaryDifference3%

- Check65 days agoChange DetectedThe page metadata revision label updated from v3.6.3 to v3.6.4, indicating a small version bump.SummaryDifference0.0%

- Check86 days agoChange DetectedThe page revision label now shows v3.6.3, indicating a minor release update to the ClinicalTrials.gov study page.SummaryDifference0.0%

Stay in the know with updates to AEB1102 Dose Escalation in Advanced Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AEB1102 Dose Escalation in Advanced Solid Tumors Clinical Trial page.